menu
    • menu
    [{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Sequoia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Full-Life Technologies","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Sequoia","highestDevelopmentStatusID":"5","companyTruncated":"Full-Life Technologies \/ Sequoia"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Focus-X Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"NTSR1","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Full-Life Technologies","amount2":0.25,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Full-Life Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Full-Life Technologies \/ Full-Life Technologies"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Focus-X Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Radiopharmaceutical Therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Full-Life Technologies","amount2":0.25,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Focus-X Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Full-Life Technologies \/ Focus-X Therapeutics"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Prosperity7 Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"225Ac-FL-020","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Prosperity7 Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Prosperity7 Ventures"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"225Ac-FL-020","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Full-Life Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"225Ac-FL-091","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Full-Life Technologies","amount2":0.56999999999999995,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Full-Life Technologies \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"225Ac-FL-020","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Full-Life Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"225Ac-FL-020","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Full-Life Technologies \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Full-Life Technologies

    Menu

    Full-Life Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225Ac-FL-091

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : SK Biopharmaceuticals

                            Deal Size : $571.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Full-Life Technologies, SK Biopharma Enter $571.5M License Agreement for FL-091

                            Details : Under the license agreement with SK Bio, for exclusive worldwide clinical research & commercialization rights to Full-Life's 225Ac-FL-020 radiopharmaceutical compound targeting NTSR1 positive cancers.

                            Brand Name : 225Ac-FL-091

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 17, 2024

                            Lead Product(s) : 225Ac-FL-091

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : SK Biopharmaceuticals

                            Deal Size : $571.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225Ac-FL-020

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track to Full-Life Technologies’ 225Ac-FL-020 for Prostate Cancer

                            Details : 225Ac-FL-020 is a novel, potential best-in-class, next-generation PSMA-targeting radionuclide drug conjugate has been granted fast track designation for the treatment of mCRPC.

                            Brand Name : 225Ac-FL-020

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 04, 2024

                            Lead Product(s) : 225Ac-FL-020

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225Ac-FL-020

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Full-Life Technologies Receives FDA Fast Track for 225Ac-FL-020 in Prostate Cancer

                            Details : 225Ac-FL-020 is a novel, potential best-in-class, next-generation PSMA-targeting radionuclide drug conjugate has been granted fast track designation for the treatment of mCRPC.

                            Brand Name : 225Ac-FL-020

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 02, 2024

                            Lead Product(s) : 225Ac-FL-020

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225Ac-FL-020

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Full-Life Technologies Gets FDA IND Clearance for 225Ac-FL-020 in Prostate Cancer

                            Details : 225Ac-FL-020 is a next-gen PSMA-targeting rdc, which is being evaluated in the early-stage clinical trial studies for the treatment of metastatic castration-resistant prostate cancer.

                            Brand Name : 225Ac-FL-020

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 29, 2024

                            Lead Product(s) : 225Ac-FL-020

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225Ac-FL-020

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Prosperity7 Ventures

                            Deal Size : $47.3 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Full-Life Technologies Announces $47.3 Million Series B Financing Led By Prosperity7

                            Details : The financing will advance the Company's radiopharmaceutical pipeline, including 225Ac-FL-020, towards Phase I clinical trials in metastatic castration-resistant prostate cancer patients.

                            Brand Name : 225Ac-FL-020

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 03, 2024

                            Lead Product(s) : 225Ac-FL-020

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Prosperity7 Ventures

                            Deal Size : $47.3 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radiopharmaceutical Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Focus-X Therapeutics

                            Deal Size : $245.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Ful...

                            Details : Focus-X is developing targeted radiopharmaceuticals-based therapeutic to treat cancer based on its proprietary peptide engineering technology. Viva also provided Focus-X with comprehensive incubation services to help it realize the transformation from co...

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            December 02, 2022

                            Lead Product(s) : Radiopharmaceutical Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Focus-X Therapeutics

                            Deal Size : $245.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTSR1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Focus-X Therapeutics

                            Deal Size : $245.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipelin...

                            Details : The acquisition expands Full-Life’s pipeline, including two compounds nearing clinical trials, provides a second innovative peptide focused discovery platform, and leverages its Radio Technology manufacturing and logistics platforms.

                            Brand Name : NTSR1

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            November 29, 2022

                            Lead Product(s) : NTSR1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Focus-X Therapeutics

                            Deal Size : $245.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Full-Life Technologies

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Sequoia

                            Deal Size : $37.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Full-Life Technologies Completes $37 Million (USD) Series A Financing to Accelerate Development of its Radioph...

                            Details : The funds will advance the lead radiopharmaceutical compounds into first-in-human studies next year and accelerate the development of the global radioisotope production and logistics capabilities.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 26, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Sequoia

                            Deal Size : $37.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth